THE Remdesivir, manufactured by the American drug giant Gilead, was one of the first drugs to appear to have some effect in shortening the recovery period of patients with COVID-19.
But a study supported by the World Health Organization found that it had “little or no effect” on deaths from the disease.
Gilead signed exploitation agreements with generic manufacturers last year in India, in Pakistan and Egypt which allow them to manufacture remedisivir to distribute it in 127 countries, most of them low-income.
Seven companies in India – the world’s largest producer of generic drugs – have been licensed to manufacture Remdesivir. They can produce up to 3.88 million injectable doses a month, according to the ministry.
India’s richest state, Maharashtra, most affected by the current outbreak, is considering imposing a full lockdown, possibly from tomorrow Monday.
After many months of lockout last year – one of the most severe in the world – India has avoided new overly strict restrictions for fear of a further deterioration of an already hit economy.
But local authorities imposed new restrictions, up to a night curfew, and looted Maharashtra over the weekend.
The chief minister of New Delhi, the capital of India, said yesterday that his government is not in favor of a lockdown, but would consider the measure in the event of a lack of hospital beds.
As he said, 65% of young patients are under 45 years old.
India has also slowed vaccine exports, with many states warning in recent days that their stocks could be depleted.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
